Pan-cancer and multiomics: advanced strategies for diagnosis, prognosis, and therapy in the complex genetic and molecular universe of cancer
- PMID: 39725831
- DOI: 10.1007/s12094-024-03819-4
Pan-cancer and multiomics: advanced strategies for diagnosis, prognosis, and therapy in the complex genetic and molecular universe of cancer
Abstract
The pan-cancer and multi-omics approach is motivated by the genetic and molecular complexity inherent in the varied types of cancer. This method presents itself as a crucial resource for advancing early diagnosis, defining prognoses and identifying treatments that share common bases between different forms of tumors. The aim of this article is to explore pan-cancer analysis in conjunction with multi-omics strategies, evaluating laboratory, computational, clinical procedures and their consequences, as well as examining the tumor microenvironment, epigenetics and future directions of these technologies in patient management. To this end, a literature review was conducted using PUBMED, resulting in the selection of 260 articles, of which 81 were carefully chosen to support this analysis. The pan-cancer methodology is applied to the study of this microenvironment with the aim of investigating its common characteristics through multiomics data. The development of new therapies depends on understanding the oncogenic pathways associated with different cancers. Thus, the integration of multi-omics and pan-cancer analyzes offers an innovative perspective in the search for new control points, metabolic pathways and markers, in addition to facilitating the identification of patterns common to multiple cancer types, allowing the development of targeted treatments. In this way, the convergence of multiomics and clinical approaches promotes a broad view of cancer biology, leading to more effective and personalized therapies.
Keywords: Biomarkers; Multi-omics; Pan-cancer; Treatment.
© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no conflicts of interest. Ethical approval: Not applicable. Informed consent: Not applicable. Institutional review board: Not applicable.
Similar articles
-
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887. Elife. 2025. PMID: 40407808 Free PMC article.
-
Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM.Sci Rep. 2025 Jan 25;15(1):3223. doi: 10.1038/s41598-025-85444-x. Sci Rep. 2025. PMID: 39863609 Free PMC article.
-
A Multi-Omics-Based Prognostic Model for Elderly Breast Cancer by Machine Learning: Insights From Hypoxia and Immunity of Tumor Microenvironment.Clin Breast Cancer. 2025 Aug;25(6):e707-e719. doi: 10.1016/j.clbc.2025.04.008. Epub 2025 Apr 15. Clin Breast Cancer. 2025. PMID: 40382303
-
Metabolic reprogramming and functional crosstalk within the tumor microenvironment (TME) and A Multi-omics anticancer approach.Med Oncol. 2025 Jul 24;42(9):373. doi: 10.1007/s12032-025-02945-5. Med Oncol. 2025. PMID: 40705181 Review.
-
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x. Respir Res. 2024. PMID: 39709425 Free PMC article. Review.
References
-
- Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173:291-304.e6. https://linkinghub.elsevier.com/retrieve/pii/S0092867418303027
-
- Wang L, Ma T, Liu W, Li H, Luo Z, Feng X. Pan-cancer analyses identify the CTC1-STN1-TEN1 complex as a protective factor and predictive biomarker for immune checkpoint blockade in cancer. Front Genet. 2022;13. https://doi.org/10.3389/fgene.2022.859617/full
-
- Wu D, Wang D, Zhang MQ, Gu J. Fast dimension reduction and integrative clustering of multi-omics data using low-rank approximation: application to cancer molecular classification. BMC Genomics. 2015;16:1022. http://www.biomedcentral.com/1471-2164/16/1022
-
- Ayton SG, Pavlicova M, Robles-Espinoza CD, Tamez Peña JG, Treviño V. Multiomics subtyping for clinically prognostic cancer subtypes and personalized therapy: A systematic review and meta-analysis. Genet Med. 2022;24:15–25. https://linkinghub.elsevier.com/retrieve/pii/S1098360021041332
-
- Southekal S, Mishra NK, Guda C. Pan-cancer analysis of human kinome gene expression and promoter DNA methylation identifies dark kinase biomarkers in multiple cancers. Cancers (Basel). 2021;13:1189. https://www.mdpi.com/2072-6694/13/6/1189
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical